Monthly Archives: April 2024

Saphnelo (anifrolumab) is a one-of-a-kind therapy by AstraZeneca for the treatment of moderate to severe systemic lupus erythematosus (SLE). In December of 2023, Saphnelo was approved for coverage under the Ontario Exceptional Access Program (EAP). SLE is an autoimmune condition … Continue reading →

On December 4, 2023, Health Canada approved Pfizer’s Litfulo (ritlecitinib). Litfulo is a once-daily oral capsule used for the treatment of patients over 12 years old with severe alopecia areata. Alopecia areata is an autoimmune condition, where the immune system produces … Continue reading →